Compare XMTR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | APGE |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | 2021 | 2023 |
| Metric | XMTR | APGE |
|---|---|---|
| Price | $98.71 | $133.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $58.60 | ★ $109.67 |
| AVG Volume (30 Days) | 679.5K | ★ 5.4M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $18.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $30.63 | $34.34 |
| 52 Week High | $99.88 | $134.32 |
| Indicator | XMTR | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 80.60 |
| Support Level | $56.76 | $80.52 |
| Resistance Level | $99.65 | N/A |
| Average True Range (ATR) | 5.36 | 0.42 |
| MACD | -0.07 | -1.40 |
| Stochastic Oscillator | 75.59 | 80.12 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.